Clinical and Molecular Hepatology

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations”: Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Dae Won Jun; Clin Mol Hepatol 2026;32(3):e389-e391.
Published online February 5, 2026; DOI: https://doi.org/10.3350/cmh.2026.0143

PDF

Citations

Citations to this article as recorded by

Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation
Joo Hyun Oh, Jonghyun Lee, Miyoung Choi, Kento Imajo, Masato Yoneda, Hideki Fujii, Hyo Young Lee, Eileen L. Yoon, Mimi Kim, Dae Won Jun
Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef

1,124 View
52 Download
Crossref

Steatotic liver disease

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”: Ji Won Han, Dae Won Jun; Clin Mol Hepatol 2025;31(2):e152-e154.
Published online December 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.1160

PDF

Citations

Citations to this article as recorded by

Non-invasive Risk-based Surveillance Strategy for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
Ji Won Han
The Korean Journal of Gastroenterology.2026; 86(1): 62. CrossRef

8,860 View
63 Download
1 Web of Science
Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”: Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip; Clin Mol Hepatol 2025;31(1):256-260.
Published online September 3, 2024; DOI: https://doi.org/10.3350/cmh.2024.0737

PDF

Citations

Citations to this article as recorded by

Interest of biochemical monitoring of liver function for patients under anti-tuberculosis treatment
Alsayed Ahmad Dana, Chikhi Aicha, Sai Touba, Benzitouni Aicha, Aoues Khadidja, Khelfi Abderrezak
Drug and Chemical Toxicology.2026; : 1. CrossRef
Immune escape mechanisms revealed by multifunctional nanoprobes targeting PD‐L1 in hepatic cancer progression
Yiteng Meng, Liwen Jing, Yeda Chen, Shenggang Zhan, Feng Xiong, Wenbiao Chen
VIEW.2026;[Epub] CrossRef
Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma
Xiaohui Yu, Xiaoyan Chen, Hui Guo, Xia Jin, Pingping Tan, Longwu Zeng, Yan He, Junjun Li
British Journal of Pharmacology.2026; 183(16): 4989. CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef

9,130 View
85 Download
Crossref

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact: Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong; Clin Mol Hepatol 2021;27(2):273-277.
Published online February 1, 2021; DOI: https://doi.org/10.3350/cmh.2021.0019

PDF

Citations

Citations to this article as recorded by

Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter
Jimmy Che-To Lai, Anna S.F. Lok
Hepatology.2026; 83(1): 11. CrossRef
Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL)
Guifeng Li, Rong Ren, Jie Liu, Jia Li
Journal of Clinical Medicine.2026; 15(6): 2164. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States
Kevin Pak, Ryan Sachar, Sammy Saab
Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
Wen-Juei Jeng, Grace Lai-Hung Wong
Hepatology Communications.2023; 7(3): e0060. CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef
A global investment case for hepatitis B elimination: a modelling study
Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott
The Lancet Gastroenterology & Hepatology.2023; 8(10): 932. CrossRef
Correlation between contrast-enhanced ultrasound perfusion parameters and EphB4 expression in hepatocellular carcinoma lesions
Chen-ZhuoYa Sheng, Gen-Xin Yao, Xin-Rong Zhang, Dong Li
World Chinese Journal of Digestology.2021; 29(18): 1084. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424. CrossRef